IKT Stock Overview
A clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Inhibikase Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.60 |
| 52 Week High | US$3.82 |
| 52 Week Low | US$0.79 |
| Beta | 1.33 |
| 11 Month Change | 15.48% |
| 3 Month Change | -6.43% |
| 1 Year Change | -35.74% |
| 33 Year Change | -88.75% |
| 5 Year Change | n/a |
| Change since IPO | -97.31% |
Recent News & Updates
Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25
Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Inhibikase Therapeutics prices stock offering at $3
Jun 16Shareholder Returns
| IKT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.6% | 3.4% | -2.4% |
| 1Y | -35.7% | 17.1% | 17.5% |
Return vs Industry: IKT underperformed the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: IKT underperformed the US Market which returned 17.2% over the past year.
Price Volatility
| IKT volatility | |
|---|---|
| IKT Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IKT's share price has been volatile over the past 3 months.
Volatility Over Time: IKT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 9 | Milton Werner | www.inhibikase.com |
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. Fundamentals Summary
| IKT fundamental statistics | |
|---|---|
| Market cap | US$11.83m |
| Earnings (TTM) | -US$19.20m |
| Revenue (TTM) | US$195.98k |
58.9x
P/S Ratio-0.6x
P/E RatioIs IKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IKT income statement (TTM) | |
|---|---|
| Revenue | US$195.98k |
| Cost of Revenue | US$13.52m |
| Gross Profit | -US$13.32m |
| Other Expenses | US$5.88m |
| Earnings | -US$19.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.66 |
| Gross Margin | -6,796.37% |
| Net Profit Margin | -9,797.30% |
| Debt/Equity Ratio | 4.1% |
How did IKT perform over the long term?
See historical performance and comparison